At the news
? BULLISHIMPACT 7/10 8-K filed Mar 11, 2026 at 16:32 ET
Pliant Therapeutics reported fourth quarter 2025 financial results and provided a corporate update, highlighting positive Phase 1 data for its oncology drug PLN-101095 in checkpoint inhibitor-refractory solid tumors. The company initiated a Phase 1b indication expansion trial and reported reduced R&D and G&A expenses, leading to a narrower net loss. It has $192.4 million in cash, sufficient to fund operations into the second half of 2028.
- PLN-101095 showed deep and durable responses in ICI-refractory patients, with 4 responders (1 complete, 3 partial) out of 10 patients across multiple tumor types.
- Phase 1b indication expansion trial initiated in NSCLC, renal cell carcinoma, and high tumor mutational burden tumors, with first patient enrollment expected in Q2 2026 and interim data in 2027.
- Q4 2025 R&D expenses decreased to $15.6M from $38.8M YoY due to discontinuation of BEACON-IPF.
- Q4 2025 G&A expenses decreased to $8.0M from $14.5M YoY due to workforce restructuring.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access